Supprelin® LA (histrelin acetate subcutaneous implant)

Supprelin LA (histrelin acetate 50 mg subcutaneous implant) is covered only for the FDA‑approved use: treatment of children with central precocious puberty and is not covered for other indications. Coverage is limited to one 50 mg implant placed subcutaneously in the upper arm every 12 months with 12‑month approval, and documentation of the central precocious puberty diagnosis is required.

"Supprelin LA (histrelin acetate subcutaneous implant) is indicated for the treatment of children with central precocious puberty."

Sign up to see full coverage criteria, indications, and limitations.